MedTrace Logo

SWITCH: Apixaban vs Vitamin K in HM3

NCT07471139 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2026-03-13

No results posted yet for this study

Summary

This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.

Conditions

Interventions

DRUG

Warfarin

Warfarin dose titrated for an International Normalized Ratio (INR) \>= 1.8

DRUG

Apixaban

Apixaban 5 mg bid (twice a day)

Sponsors & Collaborators

Principal Investigators

  • Nir Uriel, MD · New York Presbyterian / Columbia University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-06-30
Completion
2029-06-30
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07471139 on ClinicalTrials.gov